Intellia Therapeutics, Inc. (NTLA) FY2025 10-K Annual Report
Intellia Therapeutics, Inc. (NTLA) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Intellia Therapeutics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: biotechnology firm developing CRISPR-based in vivo genome editing therapies targeting severe diseases
- • New emphasis on Phase 3 products lonvo-z and nex-z for hereditary angioedema and transthyretin amyloidosis, with commercial launch preparation for lonvo-z in H1 2027
- • Strategic focus shifted towards advancing first-in-class systemic CRISPR therapies with single IV infusions in outpatient settings
- • Employee count increased with shares issued to 116.3M from 102.0M year-over-year, net loss reduced to $412.7M from $519.0M in 2024
- • Collaboration revenue grew to $67.7M from $57.9M, signaling stronger partner-based funding streams in 2025
Management Discussion & Analysis
- • No revenue or profitability data provided for fiscal year 2026
- • No segment performance or cash flow details disclosed
- • No capital allocation information such as buybacks, dividends, or capex mentioned
- • Forward-looking statements referenced but no specific management outlook or guidance included
Risk Factors
- • Regulatory risk: potential impact of SEC scrutiny on forward-looking statements disclosed in 2026 10-K
- • Geopolitical/macroeconomic risk: $117.7M common stock shares remain under the amended 2022 Sale Agreement with Jefferies exposure to market volatility
- • Operational risk: $195.1M committed lease payments starting mid-2026 for new Cambridge office/lab space could pressure cash flow
- • Competitive risk: reliance on Regeneron collaboration contributing $23.7M in cost reimbursements subject to partnership risks
- • Financial risk: $394.7M net cash used in operating activities in 2025, with runway into H2 2027 excluding milestones or new capital raises
Intellia Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$68M
▲ +16.9% YoY
Net Income
-$413M
▲ +20.5% YoY
Operating Margin
-651.7%
▲ +27143bp YoY
Net Margin
-609.9%
▲ +28691bp YoY
ROE
-61.5%
▼ -194bp YoY
Total Assets
$842M
▼ -29.3% YoY
EPS (Diluted)
$-3.81
▲ +27.4% YoY
Operating Cash Flow
-$395M
▼ -13.1% YoY
Source: XBRL data from Intellia Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Intellia Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.